KRAS and pancreatic neoplasm: Drug combinations comprising KRAS G12C inhibitors and the FAK inhibitor IN10018 showed promising synergistic effects against diverse cancer cells and multiple cancer models, including NSCLC, CRC, and pancreatic cancer.